NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous ZMA001 in Healthy Subjects

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts




Sponsoring Institute

National Heart, Lung and Blood Institute (NHLBI)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: 60 Years

Referral Letter Required


Population Exclusion(s)

Pregnant Women


human monoclonal antibody (IgG1)

Recruitment Keyword(s)



Pulmonary arterial hypertension PAH

Investigational Drug(s)

ZMA001 mAb

Investigational Device(s)



Drug: ZMA001 (BC-NKA-20008)
Other: Placebo

Supporting Site

National Heart, Lung, and Blood InstituteZymedi, Co., Ltd.


A number of diseases can cause a type of lung injury called pulmonary arterial hypertension (PAH). Most people who develop PAH do not survive more than a few years. A new study drug (ZMA001) may help. ZMA001 is a monoclonal antibody. This type of drug consists of proteins, made in a facility, that are very similar to proteins in a human body. But before giving ZMA001 to people sick with PAH, researchers want to find out how the drug affects healthy people.


To test a drug (ZMA001) in healthy volunteers.


Healthy adults aged 18 to 60 years.


Participants will be screened. They will have a physical exam with blood tests. They will have a urine test for drug use. They will have a test of their heart function.

Participants will come to the clinic for 1 inpatient visit of up to 48 hours.

ZMA001 is a liquid administered through a tube attached to a needle inserted into a vein in the arm. Participants will receive this drug only once, during their inpatient stay. Some participants will receive the drug; others will receive a placebo. A placebo is a treatment that looks just like the real drug but contains no medicine. Participants will not know which treatment they are getting.

After a screening visit, participants will have 1 inpatient visit and up to 6 outpatient visits over 16 weeks after receiving the treatment. Blood draws and other tests will be repeated. Each outpatient visit is approximately 2 hours long.

This study is the first time ZMA001 will be administered to people.

--Back to Top--



In order to be eligible to participate in this study, an individual must meet all of the following criteria:

1. Stated willingness to comply with all study procedures and availability for the duration of the study

2. Male* or female, aged 18 to 60 years, inclusive

3. In good general health as evidenced by medical history

4. Females of childbearing potential agree to use an accepted method of contraception (see below) throughout study participation and for 120 days after study drug infusion.

5. Males sexually active with a female partner must agree to use a condom with spermicide for 120 days after study drug infusion or be surgically sterile for at least 90 days before screening. Males must also agree to not donate sperm for 120 days after study drug administration.

6. Agreement to adhere to Lifestyle Considerations throughout study duration

7. Ability of subject to understand and the willingness to sign a written informed consent document.

*Enrollment of healthy male subjects will be limited to no more than 14 out of the total study cohort of 32 in order to ensure an adequate representation of female subjects.

Accepted methods of contraception for females of childbearing potential:

--Use of an implanted or intrauterine hormonal device for at least 30 consecutive days before study drug infusion

--Use of oral, patch or injectable contraceptives or a vaginal hormonal device for at least 30 consecutive days before study drug infusion

--Use of a non-hormonal intrauterine device for at least 30 consecutive days before study drug infusion

--Two barrier methods such as a diaphragm with spermicide or a condom with spermicide


An individual who meets any of the following criteria prior to informed consent will be excluded from participation in this study:

1. Pregnancy or lactation. Females of childbearing potential must have a negative serum B-human chorionic gonadotropin test no more than 48 hours from study drug infusion.

2. History of severe drug or excipient allergy or hypersensitivity

3. Known allergy to any of the components of the investigational drug or placebo

4. Recent infection or febrile illness within the past 14 days

5. Treatment with another investigational drug within the past 30 days or 5 half-lives, whichever is longer

6. Any vaccination within the past 4 weeks or receipt of a live-attenuated vaccine within the past 6 months

7. Use of tobacco products within the past 3 months

8. Recreational drug use within the past 6 months or positive urine drug screen at Screening Visit

9. History of alcohol abuse within the past 2 years

10. Current clinically significant medical illness that is uncontrolled despite appropriate medical treatment including (but not limited to) hematologic, oncologic, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, infectious, hepatic, dermatologic, psychiatric, neurologic, autoimmune or allergic disease

11. Body mass index less than 17 or greater than 32 kg/m^2

12. Clinically significant abnormal results on clinical blood testing completed at the Screening Visit

13. Electrocardiographic evidence of clinically relevant heart disease

14. Diabetes mellitus requiring medical treatment

15. Received another monoclonal antibody in the past 30 days

16. Use of herbal supplements, or similar products within the past 2 weeks

17. Blood donation equal to or above 500 mL within 2 months prior to dosing.

18. Any other finding that, in the judgment of the Investigator, would increase the risk of having an adverse outcome from participating in the study.

--Back to Top--


Not Provided

--Back to Top--


Principal Investigator

Referral Contact

For more information:

Jason M. Elinoff, M.D.
National Heart, Lung and Blood Institute (NHLBI)
(301) 978-6468

Sandra Cooper Bennett, R.N.
National Heart, Lung and Blood Institute (NHLBI)
National Institutes of Health
Building 10
Room 6-3152
10 Center Drive
Bethesda, Maryland 20892
(240) 328-0465

Office of Patient Recruitment
National Institutes of Health Clinical Center (CC)
Building 61, 10 Cloister Court
Bethesda, Maryland 20892
Toll Free: 1-800-411-1222
Local Phone: 301-451-4383
TTY: TTY Users Dial 7-1-1

Clinical Trials Number:


--Back to Top--